ArticleEpigenetics2022
Using Cg05575921 methylation to predict lung cancer risk: a potentially bias-free precision epigenetics approach.
Article in Epigenetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 12 citations in OpenAlex.
- A DNA Methylation-based algorithm Improves Lung Cancer risk prediction in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.Lung cancer (Amsterdam, Netherlands) · 2026Article
- Blood-based DNA methylation marker model for short-term and long-term lung cancer risk prediction.BMC medicine · 2026Article
- Examining the timing of trauma, PTSD onset, and DNA methylation: A multicohort investigation of candidate CpG sites.Journal of psychiatric research · 2025Article
- Personalized medicine for cardiovascular diseases: how next generation epigenetic technologies can contribute?Epigenomics · 2025Review
- The Effect of Clinical Factors on the Reversion of Cg05575921 Methylation in Smoking Cessation.Epigenomes · 2025Article
- Te Oranga Pūkahukahu research programme: intentional steps towards a national equity-focused lung cancer screening programme in Aotearoa New Zealand.Journal of the Royal Society of New Zealand · 2025Article
- Article
- Epigenomic insights into common human disease pathology.Cellular and molecular life sciences : CMLS · 2024Review
- Epigenetic biomarkers for smoking cessation.Addiction neuroscience · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
The decision to engage in lung cancer screening (LCS) necessitates weighing benefits versus harms. Previously, clinicians in the United States have used the PLCOM
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.